{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:27:51Z","timestamp":1789547271593,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"DOI":"10.1097\/qai.0b013e3182433288","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T18:42:56Z","timestamp":1322851376000},"page":"393-399","source":"Crossref","is-referenced-by-count":50,"title":["Social and Environmental Predictors of Plasma HIV RNA Rebound Among Injection Drug Users Treated With Antiretroviral Therapy"],"prefix":"10.1097","volume":"59","author":[{"given":"M-J.","family":"Milloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Krusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Guillemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210131","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/00002030-200409030-00013","article-title":". All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population.","volume":"18","author":"Keiser","year":"2004","journal-title":"AIDS"},{"key":"R2-12-20210131","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/QAI.0b013e3181b31b8a","article-title":". Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men.","volume":"52","author":"Malta","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-12-20210131","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":". Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 cell count is 0.200 to 0.350 x 10(9) cellsL.","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"R4-12-20210131","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/S0102-311X2006000400002","article-title":"Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death.","volume":"22","author":"Vlahov","year":"2006","journal-title":"Cad Saude Publica"},{"key":"R5-12-20210131","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(10)60832-X","article-title":". Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.","volume":"376","author":"Wolfe","year":"2010","journal-title":"Lancet"},{"key":"R6-12-20210131","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":". Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"R7-12-20210131","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":". Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-12-20210131","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":". Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"R9-12-20210131","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/QAI.0b013e3181f2ac87","article-title":". Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.","volume":"55","author":"Lima","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-12-20210131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1293.2008.00650.x","article-title":". Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.","volume":"10","author":"Smith","year":"2009","journal-title":"HIV Med"},{"key":"R11-12-20210131","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/QAD.0b013e3282f366ff","article-title":". Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.","volume":"22","author":"Gardner","year":"2008","journal-title":"AIDS"},{"key":"R12-12-20210131","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/650537","article-title":". Predicting virologic failure in an HIV clinic.","volume":"50","author":"Robbins","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R13-12-20210131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(10)60829-X","article-title":". Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.","volume":"376","author":"Altice","year":"2010","journal-title":"Lancet"},{"key":"R14-12-20210131","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1468-1293.2009.00701.x","article-title":". Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.","volume":"10","author":"Weber","year":"2009","journal-title":"HIV Med"},{"key":"R15-12-20210131","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/09540120802459762","article-title":". HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.","volume":"21","author":"Chander","year":"2009","journal-title":"AIDS Care"},{"key":"R16-12-20210131","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00126334-200304150-00009","article-title":". Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.","volume":"32","author":"Palepu","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-12-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00042560-200107010-00006","article-title":". Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.","volume":"27","author":"Lucas","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-12-20210131","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","article-title":". Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.","volume":"131","author":"Lucas","year":"1999","journal-title":"Ann Intern Med"},{"key":"R19-12-20210131","first-page":"S135","article-title":"Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration.","volume":"117","author":"Galea","year":"2002","journal-title":"Public Health Rep"},{"key":"R20-12-20210131","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.socscimed.2004.12.024","article-title":". The social structural production of HIV risk among injecting drug users.","volume":"61","author":"Rhodes","year":"2005","journal-title":"Soc Sci Med"},{"key":"R21-12-20210131","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(10)60743-X","article-title":". HIV and risk environment for injecting drug users: the past, present, and future.","volume":"376","author":"Strathdee","year":"2010","journal-title":"Lancet"},{"key":"R22-12-20210131","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.280.6.547","article-title":". Barriers to use of free antiretroviral therapy in injection drug users.","volume":"280","author":"Strathdee","year":"1998","journal-title":"JAMA"},{"key":"R23-12-20210131","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.292.10.1175-b","article-title":". Staging for antiretroviral therapy among HIV-infected drug users.","volume":"292","author":"Wood","year":"2004","journal-title":"JAMA"},{"key":"R24-12-20210131","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jama.300.5.550","article-title":". Highly active antiretroviral therapy and survival in HIV-infected injection drug users.","volume":"300","author":"Wood","year":"2008","journal-title":"JAMA"},{"key":"R25-12-20210131","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1086\/507680","article-title":". A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.","volume":"194","author":"Gross","year":"2006","journal-title":"J Infect Dis"},{"key":"R26-12-20210131","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/00002030-200308150-00003","article-title":". Virological rebound after suppression on highly active antiretroviral therapy.","volume":"17","author":"Mocroft","year":"2003","journal-title":"AIDS"},{"key":"R27-12-20210131","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00126334-200004010-00016","article-title":". Adherence to triple therapy and viral load response.","volume":"23","author":"Low-Beer","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-12-20210131","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00002030-200102160-00021","article-title":". Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.","volume":"15","author":"Palepu","year":"2001","journal-title":"AIDS"},{"key":"R29-12-20210131","first-page":"656","article-title":". Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.","volume":"169","author":"Wood","year":"2003","journal-title":"CMAJ"},{"key":"R30-12-20210131","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3851\/IMP1614","article-title":". Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.","volume":"15","author":"Krusi","year":"2010","journal-title":"Antivir Ther"},{"key":"R31-12-20210131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.drugpo.2009.08.003","article-title":". Social and structural determinants of HAART access and adherence among injection drug users.","volume":"21","author":"Krusi","year":"2010","journal-title":"Int J Drug Policy"},{"key":"R32-12-20210131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","article-title":"The risk environment: a framework for understanding and reducing drug-related harm.","volume":"13","author":"Rhodes","year":"2002","journal-title":"Int J Drug Policy"},{"key":"R33-12-20210131","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.drugpo.2008.10.003","article-title":"Risk environments and drug harms: a social science for harm reduction approach.","volume":"20","author":"Rhodes","year":"2009","journal-title":"Int J Drug Policy"},{"key":"R34-12-20210131","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/630209","article-title":". Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.","volume":"49","author":"Roux","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R35-12-20210131","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00002030-200401001-00004","article-title":". Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse.","volume":"18","author":"Hinkin","year":"2004","journal-title":"AIDS"},{"key":"R36-12-20210131","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jurban\/jti076","article-title":". Access and utilization of HIV treatment and services among women sex workers in Vancouvers Downtown Eastside.","volume":"82","author":"Shannon","year":"2005","journal-title":"J Urban Health"},{"key":"R37-12-20210131","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1360-0443.2010.02905.x","article-title":". Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users.","volume":"105","author":"Uhlmann","year":"2010","journal-title":"Addiction"},{"key":"R38-12-20210131","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/09540120412331319778","article-title":". Determinants of HAART discontinuation among injection drug users.","volume":"17","author":"Kerr","year":"2005","journal-title":"AIDS Care"},{"key":"R39-12-20210131","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/infdis\/jir032","article-title":". Dose-response effect of incarceration events on non-adherence to HIV antiretroviral therapy among injection drug users.","volume":"203","author":"Milloy","year":"2011","journal-title":"J Infect Dis"},{"key":"R40-12-20210131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.drugpo.2006.11.019","article-title":". Public injection settings in Vancouver: physical environment, social context and risk.","volume":"18","author":"Small","year":"2007","journal-title":"Int J Drug Policy"},{"key":"R41-12-20210131","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAI.0b013e318160d5ae","article-title":". Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico.","volume":"47","author":"Strathdee","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-12-20210131","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2105\/AJPH.2007.129858","article-title":". Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy.","volume":"99","author":"Shannon","year":"2009","journal-title":"Am J Public Health"},{"key":"R43-12-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09595230801956157","article-title":". Incarceration experiences in a cohort of active injection drug users.","volume":"27","author":"Milloy","year":"2008","journal-title":"Drug Alcohol Rev"},{"key":"R44-12-20210131","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.1989.03430120118033","article-title":"Methadone treatment and acquired immunodeficiency syndrome.","volume":"262","author":"Cooper","year":"1989","journal-title":"JAMA"},{"key":"R45-12-20210131","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/09540120802511869","article-title":". The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.","volume":"21","author":"Small","year":"2009","journal-title":"AIDS Care"},{"key":"R46-12-20210131","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/135965350400900503","article-title":". Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.","volume":"9","author":"Palepu","year":"2004","journal-title":"Antivir Ther"},{"key":"R47-12-20210131","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.284.2.179","article-title":". Directly observed therapy to treat HIV infection in prisoners.","volume":"284","author":"Babudieri","year":"2000","journal-title":"JAMA"},{"key":"R48-12-20210131","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/421392","article-title":". Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community.","volume":"38","author":"Springer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R49-12-20210131","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11524-010-9438-4","article-title":". Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.","volume":"87","author":"Springer","year":"2010","journal-title":"J Urban Health"},{"key":"R51-12-20210131","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/QAI.0b013e3181f9c1f0","article-title":". Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes.","volume":"55","author":"Montaner","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R53-12-20210131","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.qai.0000248351.10383.b7","article-title":". Predictors of antiretroviral treatment failure in an urban HIV clinic.","volume":"44","author":"Robbins","year":"2007","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182433288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T19:20:41Z","timestamp":1741980041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201204010-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182433288","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4,1]]}}}